MCW inventors have developed novel small molecule therapeutics that will help treat pancreatic and other cancers. The new metformin analogs are selectively designed to accumulate in tumor mitochondria and inhibit OXPHOS via mitochondrial complex 1, which affords cytostatic and radiosensitization properties against tumor cells.
Historically, mitochondria were thought to be dispensable in tumor cells. However, certain cancers are now known to be highly dependent on mitochondrial metabolism, making OXPHOS an emerging druggable target for cancer therapy. The “mito-metformin” compounds described here were designed with tumor-specific OXPHOS inhibition in mind and have shown efficacy in both in vitro and in vivo pancreatic cancer models.
These cytostatic compounds have significant potential as therapies in combination with cytotoxic agents and/or radiation therapy for pancreatic or other cancers.
- Selective to tumor cells with no toxicity to normal cells
- Nanomolar potency
- Sensitizes tumor cells to radiation treatment
MCW Office of Technology Development: https://www.mcw.edu/departments/technology-development
Name: Landon Olp, PhD
Title: Licensing Manager
Phone: (414) 955-4884